Evidence map›Paper›PMID 35420356›Full record

ArticleArchives of gynecology and obstetrics2022

Burden of CIN2+ diagnoses and conizations in women aged 18-45 years-a retrospective secondary data analysis of German statutory health insurance claims data.

Miriam Reuschenbach, Anna-Janina Stephan, Kunal Saxena, Vimalanand S Prabhu, Christian Jacob, Kim Maren Schneider, Wolfgang Greiner, Regine Wölle, Monika Hampl

Open access · hybridAbstract read
In one paragraph

Article in Archives of gynecology and obstetrics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.9field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Review
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 2 countries.

Miriam Reuschenbach *Global Medical and Scientific Affairs, MSD Sharp & Dohme GmbH, Levelingstr. 4a, 81673, Munich, Germany. miriam.reuschenbach@msd.de.
Anna-Janina Stephan *Department of Market Access, MSD Sharp & Dohme GmbH, Munich, Germany.
Kunal SaxenaCenter for Observational and Real-World Evidence (CORE), Merck & Co., Inc., Kenilworth, NJ, USA.
Vimalanand S PrabhuCenter for Observational and Real-World Evidence (CORE), Merck & Co., Inc., Kenilworth, NJ, USA.
Christian JacobEU Real World Evidence, Xcenda GmbH, Hanover, Germany.
Kim Maren SchneiderEU Real World Evidence, Xcenda GmbH, Hanover, Germany.
Wolfgang GreinerDepartment of Health Economics and Health Care Management, Bielefeld School of Public Health, Bielefeld University, Bielefeld, Germany.
Regine WölleDepartment of Market Access, MSD Sharp & Dohme GmbH, Munich, Germany.
Monika HamplDepartment of Gynecology, University of Duesseldorf, Duesseldorf, Germany.
MSD (Germany) · DEMerck & Co., Inc., Rahway, NJ, USA (United States) · USBielefeld University · DEHeinrich Heine University Düsseldorf · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeHigh grade cervical intraepithelial neoplasia (CIN2+) may progress to cervical cancer. They may be detected by screening and are usually treated by conization. This study aimed at assessing annual proportions of screening, prevalent and incident CIN2+ diagnoses, as well as proportions of (re-)conizations during 24 months follow-up after conization in Germany.

methodsA descriptive retrospective claims data analysis of the years 2013-2018 was conducted using the InGef Research Database. Women aged 18-45 years with CIN2+ diagnoses were identified by ICD-10-GM codes (N87.1, N87.2, D06.-, and C53.-). Cervical conizations were identified by OPS codes (5-671.0* or 5-671.1*). Screening participation was identified by EBM codes (01730, 01733, 32819 or 32820). Annual proportions were calculated as women with the respective documented codes divided by all women in the respective age group per calendar year.

resultsOverall annual proportions of screened women spanned from 60.01 to 61.33% between 2013 and 2018. The overall annual prevalence of CIN2+ diagnoses (regardless of screening participation) ranged from 0.72 to 0.84% between 2013 and 2018, with highest proportions observed in women aged 27-45 years. Also, CIN2+ incidence was highest in women 27-45 years. Annual proportion of women undergoing conization was 0.24% in 2013 and 0.21% in 2018. During a 24-month follow-up period after conization, 2.91% of women underwent a re-conization 3 months or later after the initial conization.

conclusionThis analysis demonstrates a considerable burden of CIN2+, conizations and re-conizations in Germany, especially in women aged 27-45 years. This highlights the need for intensified prevention efforts such as expanding human papillomavirus (HPV) vaccination.

Indexed as

Papillomavirus InfectionsUterine Cervical NeoplasmsConizationData AnalysisFemaleHumansInsurance, HealthPapillomaviridaeRetrospective StudiesCervical cancer screeningCervical conizationCervical intraepithelial neoplasia (CIN)Claims data analysisGermanyHPV

Identifiers

PMID35420356
PMCPMC9633516
OpenAlexW4223926551

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.